Day Two: Wednesday March 7, 2018

REGISTRATION & COFFEE

8:00

Biomarkers & Companion Diagnostics

8:30

Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced TNBC



Yu Liang

Director, Clinical Biomarkers

 

Calithera Biosciences

9:00

Preclinical and Clinical Activity of Anti-HER3 Antibody, Seribantumab, Combined with Standard of Care in Hormone Receptor-positive, HER2-negative Breast Cancer

 

Sara Ghassemifar

Clinical Scientist

 

Merrimack Pharmaceuticals

9:30

The Continued Importance of Tissue Collection and Histopathology in Clinical Trials

Rachel Skelton

Business Development Manager, Pharma Partnerships

Leica Biosystems

MORNING REFRESHMENTS & SPEED NETWORKING

10:00

10:30

Examining the factors impacting concordance of plasma testing by next generation sequencing

 

Dan Stetson

Associate Principal Scientist

 

AstraZeneca

11:00

Challenges and Opportunities of ctDNA Plasma Assays.

 

 

Jonathan Beer

Director, Lead of Disruptive Technologies

 

Novartis

11:30

A precision medicine approach to treating HER2 mutant metastatic breast cancer with neratinib.

 

Richard Cutler

Sr. Director, Clinical Science

 

Puma Biotechnology

12:00

XMT-1522: Biomarker and Translational Aspects

Rebecca Mosher

Executive Director, Translational Medicine

 

Mersana Therapeutics

12:30

Harnessing the innate and the adaptive immune system for a complete anti-tumor response: NKTR-262 and NKTR-214

Fiore Cattaruzza

Senior Research Scientist II, Translational Medicine,

 

Nektar Therapeutics

LUNCH & NETWORKING

1:00

PANEL DISCUSSION

1:30

Participating:

Participants to be announced..

Novel Approaches in Breast Cancer Drug R&D

2:00

SY-1365, a selective, first in class, CDK7 inhibitor, offers potential novel therapeutic approaches in breast cancer

Emmanuelle diTomaso

Vice President, Translational Medicine

 

Syros Pharmaceuticals

2:30

Discovery and Development of a First-in-Class Oral Selective ERa Covalent Antagonist (SERCA) for the Treatment of ERaWT and ERaMUT Breast Cancer

 

Manav Korpal

Senior Investigator

 

H3 Biomedicine

AFTERNOON REFRESHMENTS & NETWORKING

3:00

3:30

Immunotherapy combinations in breast cancer


Joyson Karakunnel

Vice President, Clinical Sciences

 

Arcus Biosciences

4:00

Mining the Immunome of Responder Patients Yields Active Anti-Tumor Antibodies


Daniel Emerling

Senior Vice President, Research

 

Atreca

4:30

The  developing treatment for triple negative breast cancer utilizing a multi-functional immunotherapeutic platform


Mahesh Narayanan

CEO

PepVax

SUMMARY & CLOSE OF CONFERENCE

5:00

VIEW PREVIOUS DAY

DOWNLOAD EVENT GUIDE

Complete the form below to download the PDF

NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN

contact@neo-synth.com

(+1) 617.500.5172

Submitting Form...

The server encountered an error.

Request received. Please allow some time for processing - You will receive a manual response within a few hours.

Your details will not be shared with a third party

Copyright © 2016 | All content produced by: neo-synth ltd.

Registration

Biomarkers & Companion Diagnostics

Yu Liang, Calithera

Merrimack Pharmaceuticals

Digital Pathology and Image Analysis in Breast Cancer

 

Rachel Skelton

Business Development Manager, Pharma Partnerships

Leica Biosystems

Networking Break

AstraZeneca

Jonathan Beer, Novartis

Richard Cutler.

Puma Biotechnology

Rebecca Mosher, Mersana

Fiore Cattaruzza, Nektar

Lunch

Panel Discussion

Novel Approaches

Emmanuelle diTomaso, Syros

Manav Korpal, H3 Biomedicine

Networking Break

Joyson Karakunnel, Arcus

Daniel Emerling, Atreca

Mahesh Narayanan, PepVax

Close of Event

DOWNLOAD GUIDE